← Leaderboards
Alex Lyubimov
University Of Illinois At Chicago
$1,686,954
Attributed
$1,686,954
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.1M · FY2019–21$2M$1.5M$1M$500K$0
'19
'20
'21
Funding mix
By agency
NIH$1,686,954 · 2
By mechanism
N01$1,686,954 · 2
Top collaborators
No co-investigators on record.
Most similar at University Of Illinois At Chicago
Same institution · by research overlap
- Judy L. Bolton$10,491,560
- Vida Ann Henderson$867,331
- Rosemary C White-Traut$4,936,014
- Lindsey Garfield$808,082
- Angela L Tyner$9,149,817
Others in their field
Other Emerging Leaders on “In Vivo”
- Leonard Freedman · Leidos Biomedical Research, Inc.$304,459,298
- Lynn Briscoe · Leidos Biomedical Research, Inc.$94,216,744
- Leonard Freedmand · Leidos Biomedical Research, Inc.$66,248,714
- John Damon Chodera · Sloan-Kettering Inst Can Research$43,427,103
- Tony Moody · Duke University$34,777,314
- Alan D. Palkowitz · Indiana University Indianapolis$18,925,366
Research focus
In VivoPharmacokinetics And PharmacodynamicsPreventiveCharacteristicsUnited States Food And Drug AdministrationAuthorityAnti-CancerDietary SupplementsBindingAromatase InhibitorsAttenuatedBiological MarkersBone LossBreastChemopreventive AgentCancer CellBreast ImagingBcl9 GeneCancer TypeBeta CateninCell LineCell ProliferationCellsBreast Cancer Progression
Grant awards (3)
PREVENT PRECLINICAL EFFICACY AND INTERMEDIATE BIOMARKER ENDPOINTS TASK ORDER: USE OF CARNOSIC ACID AND VIVOX40 FOR BREAST CANCER PREVENTION$611,872
N01 · FY2021 · CA · contact PI
PREVENT PRECLINICAL EFFICACY AND INTERMEDIATE BIOMARKER ENDPOINTS TASK ORDER: USE OF CARNOSIC ACID AND VIVOX40 FOR BREAST CANCER PREVENTION$1,071,582
N01 · FY2020 · CA · contact PI
PREVENT - TOX$3,500
N01 · FY2019 · CA · contact PI